Toronto Dominion Bank Increases Position in Edwards Lifesciences Co. (NYSE:EW)

Toronto Dominion Bank lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 5.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 317,326 shares of the medical research company's stock after acquiring an additional 17,046 shares during the quarter. Toronto Dominion Bank owned 0.05% of Edwards Lifesciences worth $23,492,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of EW. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences during the fourth quarter worth about $26,000. Millstone Evans Group LLC purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $30,000. Catalyst Capital Advisors LLC acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $54,000. Finally, SBI Securities Co. Ltd. purchased a new position in Edwards Lifesciences during the fourth quarter worth $62,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on EW. Morgan Stanley upped their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Royal Bank of Canada reissued an "outperform" rating and issued a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their target price for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Citigroup lifted their price target on shares of Edwards Lifesciences from $84.00 to $95.00 and gave the stock a "buy" rating in a report on Thursday. Finally, Canaccord Genuity Group boosted their price objective on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a research report on Friday, April 25th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $80.20.

Insider Buying and Selling

In related news, CEO Bernard J. Zovighian sold 6,164 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the transaction, the chief executive officer now directly owns 59,083 shares of the company's stock, valued at approximately $4,106,859.33. The trade was a 9.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 400 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the transaction, the vice president now owns 22,588 shares of the company's stock, valued at approximately $1,569,414.24. This represents a 1.74% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 67,692 shares of company stock valued at $4,822,074. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Trading Down 1.7%

EW traded down $1.30 on Thursday, reaching $74.80. 4,287,182 shares of the company's stock were exchanged, compared to its average volume of 5,123,060. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $95.25. The company's 50 day moving average is $72.60 and its 200-day moving average is $71.93. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market cap of $43.88 billion, a price-to-earnings ratio of 10.73, a PEG ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. During the same period in the previous year, the firm earned $0.66 earnings per share. Edwards Lifesciences's revenue for the quarter was up 6.2% on a year-over-year basis. Equities analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.